Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Return on Equity (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Return on Equity data on record, last reported at 0.66% in Q3 2025.

  • For Q3 2025, Return on Equity fell 45.0% year-over-year to 0.66%; the TTM value through Sep 2025 reached 0.66%, down 45.0%, while the annual FY2024 figure was 1.06%, 1877.0% up from the prior year.
  • Return on Equity reached 0.66% in Q3 2025 per BTAI's latest filing, roughly flat from 0.66% in the prior quarter.
  • Across five years, Return on Equity topped out at 12.12% in Q3 2023 and bottomed at 6.88% in Q2 2023.
  • Average Return on Equity over 4 years is 1.04%, with a median of 0.8% recorded in 2024.
  • The widest YoY moves for Return on Equity: up 851bps in 2024, down -1101bps in 2024.
  • A 4-year view of Return on Equity shows it stood at 1.62% in 2022, then skyrocketed by 327bps to 3.69% in 2023, then plummeted by -76bps to 0.89% in 2024, then dropped by -26bps to 0.66% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 0.66% in Q3 2025, 0.66% in Q2 2025, and 0.72% in Q1 2025.